IN8bio, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $13.6M
- Price
- $1.38
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.43%
- Volume
- 20.7K
About
IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various forms of cancer. The company's primary therapeutic asset, INB-200, is an autologous (patient-derived) gamma-delta T cell product that has been genetically engineered and is presently undergoing a Phase I clinical study for glioblastoma and other solid tumor malignancies. Additionally, INB-100, an allogeneic (donor-derived) candidate, is also in a Phase I clinical trial, aiming to treat acute leukemia patients undergoing hematopoietic stem cell transplantation. Further development includes preclinical programs, INB-400 and INB-300, which are designed to address a range of solid tumor cancers. Established in 2016, the company initially operated as Incysus Therapeutics, Inc. before changing its name to IN8bio, Inc. in August 2020. Its corporate headquarters are located in New York, New York.
Quick stats
Shares outstanding9.9M
Computed float9.5M
Float / shares96.1%
Cash runway (months)9.1
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001740279
Websitehttps://in8bio.com
AI Summary
AI-generated1/14
minorneutralother
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
IN8bio granted a new employee a nonqualified stock option to purchase 60,000 shares as an inducement grant under Nasdaq Listing Rule 5635(c)(4), with a grant date of October 1, 2026.
The option vests over four years, with a 25% cliff at the first anniversary and the remainder in 36 monthly installments.
This is routine compensation boilerplate with no bearing on the company's clinical pipeline or financial position.